APA
Mordoh J., Pampena M. B., Aris M., Blanco P. A., Lombardo M., von Euw E. M., Mac Keon S., Yépez Crow M., Bravo A. I., O'Connor J. M., Orlando A. G., Ramello F., Levy E. M. & Barrio M. M. (2017). Phase II Study of Adjuvant Immunotherapy with the CSF-470 Vaccine Plus Bacillus Calmette-Guerin Plus Recombinant Human Granulocyte Macrophage-Colony Stimulating Factor vs Medium-Dose Interferon Alpha 2B in Stages IIB, IIC, and III Cutaneous Melanoma Patients: A Single Institution, Randomized Study. : Frontiers in immunology.
Chicago
Mordoh José, Pampena María Betina, Aris Mariana, Blanco Paula Alejandra, Lombardo Mónica, von Euw Erika María, Mac Keon Soledad, Yépez Crow Michelle, Bravo Alicia Inés, O'Connor Juan Manuel, Orlando Ana Gabriela, Ramello Franco, Levy Estrella Mariel and Barrio María Marcela. 2017. Phase II Study of Adjuvant Immunotherapy with the CSF-470 Vaccine Plus Bacillus Calmette-Guerin Plus Recombinant Human Granulocyte Macrophage-Colony Stimulating Factor vs Medium-Dose Interferon Alpha 2B in Stages IIB, IIC, and III Cutaneous Melanoma Patients: A Single Institution, Randomized Study. : Frontiers in immunology.
Harvard
Mordoh J., Pampena M. B., Aris M., Blanco P. A., Lombardo M., von Euw E. M., Mac Keon S., Yépez Crow M., Bravo A. I., O'Connor J. M., Orlando A. G., Ramello F., Levy E. M. and Barrio M. M. (2017). Phase II Study of Adjuvant Immunotherapy with the CSF-470 Vaccine Plus Bacillus Calmette-Guerin Plus Recombinant Human Granulocyte Macrophage-Colony Stimulating Factor vs Medium-Dose Interferon Alpha 2B in Stages IIB, IIC, and III Cutaneous Melanoma Patients: A Single Institution, Randomized Study. : Frontiers in immunology.
MLA
Mordoh José, Pampena María Betina, Aris Mariana, Blanco Paula Alejandra, Lombardo Mónica, von Euw Erika María, Mac Keon Soledad, Yépez Crow Michelle, Bravo Alicia Inés, O'Connor Juan Manuel, Orlando Ana Gabriela, Ramello Franco, Levy Estrella Mariel and Barrio María Marcela. Phase II Study of Adjuvant Immunotherapy with the CSF-470 Vaccine Plus Bacillus Calmette-Guerin Plus Recombinant Human Granulocyte Macrophage-Colony Stimulating Factor vs Medium-Dose Interferon Alpha 2B in Stages IIB, IIC, and III Cutaneous Melanoma Patients: A Single Institution, Randomized Study. : Frontiers in immunology. 2017.